Altimmune, Inc.
ALT
$5.61
-$0.36-6.03%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 5.00K | 5.00K | 5.00K | 5.00K | 37.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.00K | 5.00K | 5.00K | 5.00K | 37.00K |
| Cost of Revenue | 19.78M | 19.80M | 21.16M | 21.49M | 16.91M |
| Gross Profit | -19.78M | -19.80M | -21.15M | -21.48M | -16.87M |
| SG&A Expenses | 5.09M | 4.97M | 5.60M | 5.31M | 4.33M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.87M | 24.77M | 26.75M | 26.80M | 21.24M |
| Operating Income | -24.87M | -24.77M | -26.75M | -26.79M | -21.20M |
| Income Before Tax | -23.18M | -22.85M | -24.64M | -24.39M | -31.64M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -23.18M | -22.85M | -24.64M | -24.39M | -31.64M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.18M | -22.85M | -24.64M | -24.39M | -31.64M |
| EBIT | -24.87M | -24.77M | -26.75M | -26.79M | -21.20M |
| EBITDA | -24.83M | -24.73M | -26.68M | -26.69M | -21.09M |
| EPS Basic | -0.33 | -0.32 | -0.35 | -0.34 | -0.54 |
| Normalized Basic EPS | -0.20 | -0.20 | -0.22 | -0.22 | -0.21 |
| EPS Diluted | -0.33 | -0.32 | -0.35 | -0.34 | -0.54 |
| Normalized Diluted EPS | -0.20 | -0.20 | -0.22 | -0.22 | -0.21 |
| Average Basic Shares Outstanding | 71.26M | 71.08M | 70.92M | 70.80M | 58.44M |
| Average Diluted Shares Outstanding | 71.26M | 71.08M | 70.92M | 70.80M | 58.44M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
